同型半胱氨酸与高血压靶器官损害相关研究进展
Research Progress on the Correlation between Homocysteine and Hypertensive Target Organ Damage
DOI: 10.12677/ACM.2023.13122832, PDF, HTML, XML, 下载: 111  浏览: 153 
作者: 杨超慧, 梁晓慧*:新疆医科大学第一附属医院心血管病中心,新疆 乌鲁木齐
关键词: 原发性高血压同型半胱氨酸高血压靶器官损害Essential Hypertension Homocysteine Hypertensive Target Organ Damage
摘要: 高血压作为全球性卫生问题,其导致的靶器官损害与患者预后密不可分,除了严格的降压管理,其他相关因素对高血压相关靶器官损害的影响越来越受到人们的重视。同型半胱氨酸(homocysteine, Hcy)自1932年被发现以来,其在高血压、心脑血管疾病中的致病作用被越来越多的研究证实。HHcy在高血压患病人群中患病率居高不下,这些人群中靶器官损害,及心脑血管并发症发生率较普通高血压患者高。本文将对Hcy、Hcy血症(hyperhomocysteinemia, HHcy)、H型高血压、高血压靶器官损害以及伴有HHcy的高血压患者的靶器官损害的相关研究进展进行综述。
Abstract: Hypertension is a global health problem, and the target organ damage caused by it is closely related to the prognosis of patients. In addition to strict antihypertensive management, the influence of other related factors on the target organ damage related to hypertension has been paid more and more attention. Since homocysteine (Hcy) was discovered in 1932, its pathogenic role in hyperten-sion and cardiovascular and cerebrovascular diseases has been confirmed by more and more stud-ies. The prevalence of HHcy is high in hypertensive patients, and the incidence of target organ damage and cardiovascular and cerebrovascular complications in these patients is higher than that in ordinary hypertensive patients. This article will review the research progress of Hcy, hyperho-mocysteinemia (HHcy), H-type hypertension, hypertensive target organ damage and target organ damage in hypertensive patients with HHcy.
文章引用:杨超慧, 梁晓慧. 同型半胱氨酸与高血压靶器官损害相关研究进展[J]. 临床医学进展, 2023, 13(12): 20122-20127. https://doi.org/10.12677/ACM.2023.13122832

1. 原发性高血压流行病学现状

一项覆盖全球195个国家和地区的疾病负担研究显示,高血压是导致死亡和残疾的首要危险因素 [1] 。就国内的情况而言,中国高血压调查(China Hypertension Survey, CHS)显示:2012~2015年我国18岁及以上居民高血压的粗患病率达到了27.9%,并且据估计,这一数据呈逐年增高的趋势。每年平均新增高血压患者近1000万 [2] [3] 。高血压这一全球性的卫生问题,备受世界人民的关注。有研究对7237名高血压患者,随访5.3 ± 4.5年后发现,高血压靶器官损伤累及多个部位是发生心血管事件的独立危险因素 [4] 。故充分评估靶器官损害对高血压患者有重要意义。

2. Hcy及HHcy

Hcy是一种主要存在于血浆中的含硫氨基酸,是蛋氨酸和半胱氨酸代谢的中间产物,产生于细胞甲基化过程中。这种物质只能由蛋氨酸转变而来,人体内不能合成蛋氨酸,必须从食物中获取。Hcy有三种主要的代谢命运:再甲基化为甲硫氨酸,进入半胱氨酸生物合成途径,或成为释放到细胞外介质中。显然,Hcy的第三种代谢命运是尿液和血浆等细胞外液中总Hcy浓度增加的直接原因。当其代谢中任何一环出现异常:摄入过多,酶异常或缺乏维生素B12、叶酸等都会导致血中浓度升高。

通常Hcy的正常参考范围在5至15 mmol/L。HHcy的定义存在争议,一般定义为血浆Hcy ≥ 15 mmol/L,指南也以此标准作为高血压患者血清Hcy水平干预起点 [2] 。但也有已知定义为血浆Hcy ≥ 10 mmol/L。H型高血压是指合并HHcy (≥10 umol/L)的高血压 [5] 。在我国,H型高血压占高血压患者的大部分。且已有研究表明H型高血压可显著增加心脑血管事件尤其是脑卒中的发生风险 [6] 。我国一项慢性病队列研究发现,中国人群中单纯血压水平升高可以使脑卒中风险增至9.7倍,单纯血Hcy水平升高(≥10 μmol/L)可以使脑卒中风险增至3.5倍,但高血压患者同时合并高Hcy可使脑卒中和卒中死亡风险分别增至12.7倍和11.7倍 [6] 。

目前的研究表明,HHcy的病因复杂,分为遗传性和非遗传性两大类,可自胎儿到老年发病,人群总体患病率高达5% [7] 。主要的病因有:遗传性HHcy分为酶缺陷和辅酶缺陷两大类,酶缺陷以胱硫醚β-合成酶、亚甲基四氢叶酸还原酶、蛋氨酸腺苷转移酶缺陷最为常见,辅酶缺陷以钴胺素和叶酸代谢障碍最为常见 [8] [9] 。胱硫醚β-合成酶缺乏症、亚甲基四氢叶酸还原酶缺乏症和蛋氨酸腺苷转移酶缺乏症表现为单纯HHcy,而钴胺素代谢障碍则可导致甲基丙二酸血症合并HHcy血症。非遗传性因素如营养不良、长期素食导致的营养素缺乏(如叶酸、维生素B6、钴胺素、甜菜碱缺乏)、衰老、慢性胃肠疾病、肝病、肾病、恶性肿瘤、药物(如异烟肼、甲氨蝶呤)以及不良生活方式(如长期吸烟、酗酒等),也可以引起程度不同的HHcy [10] 。

3. H型高血压的流行病学

梁喆等人进行了纳入33项H型高血压的相关研究,得出结论中国H型高血压在高血压人群中的比率73.1%,而在普通人群中总体患病率为26.9%。并且≥65岁的老年人、男性、少数民族、内陆、西部、北部和农村地区中患病率更高 [11] 。

4. 高血压介导的靶器官损害

高血压介导的靶器官损害(hypertension-mediated organ damage, HMOD),具体定义为血压升高引起的动脉血管系统和/或其供应器官的结构或功能改变,靶器官包括大脑、心脏、肾脏、中央和外周动脉以及眼 [12] 。中国高血压防治指南(2018年修订版)》将靶器官损害作为高血压诊断评估的重要内容,特别强调早期检出无症状性亚临床靶器官损害 [2] 。常见评估内容包颈动脉内膜中层厚度(carotid intima-media thickness, cIMT)、脉搏波传导速度(pulse wave velocity, PWV)、踝臂血压指数(ankle-brachial index, ABI)、左心室肥厚(left ventricular hypertrophy, LVH)、估算的肾小球滤过率(estimated glomerular filtration rate, eGFR)、微量白蛋白尿、尿白蛋白排出量或尿白蛋白与肌酐比值(urinary albumin-to-creatinine ratio, UACR)、眼底及头颅影像学检查。

1969年,基尔默·S·麦卡利(Kilmer S. McCully)博士已经证明了一名HHcy儿童的血管病变 [13] 。到目前为止,HHcy已被证明与多种高血压介导的靶器官损害(HMOD)有关,包括动脉粥样硬化 [14] 、脑卒中 [15] 、和肾功能障碍 [16] 等。我国一项慢性病队列研究发现,中国人群中单纯血压水平升高可以使脑卒中风险增至9.7倍,单纯血Hcy水平升高(≥10 μmol/L)可以使脑卒中风险增至3.5倍,但高血压患者同时合并高Hcy可使脑卒中和卒中死亡风险分别增至12.7倍和11.7倍。对中国东北农村成人HHcy的患病率及其与高血压的关系进行研究,结论提示血清Hcy水平与高血压风险独立相关,特别是男性,这提示Hcy可能是高血压的危险因素 [17] 。有研究者基于来自中国人口纵向队列的3913名参与者的样本描述了性别特定的Hcy与高血压的因果关系 [18] 。中国的其他研究也表明Hcy水平与高血压呈正相关 [19] [20] [21] 。

1) Hcy与动脉硬化

目前现有的研究还提示了Hcy在非高血压人群中的血管损伤相关性 [22] [23] ,Ren Z等人针对上海居民的研究显示:Hcy水平较高和HHcy的存在与脉搏波速度相关,并且在按性别或高血压状态划分的亚组中可以观察到显著的正相关。这提示血清Hcy水平和HHcy水平可以作为动脉僵硬的一个有价值的指标,不受性别和高血压状态的影响 [24] 。

2) Hcy与肾损害

血清Hcy水平受肾功能的影响,并且HHcy会加重肾功能损害。Hcy主要通过肝脏和肾脏排泄。因此,肾功能恶化会导致Hcy的异常积聚。同时,Hcy的积聚会导致动脉粥样硬化,进而损害肾功能,陷入一个恶性循环。有研究表明,CKD患者的HHcy患病率高于正常人群 [23] 。一项有3602名参与者的为期5年的前瞻性研究,其主要目的是观察HHcy对肾功能的影响,最终研究结果发现HHcy是肾功能下降的独立危险因素 [25] 。另有一项回顾性研究观察了7240名高血压患者,其中约半数患有Hcy,结果提示:Hcy浓度升高会增加高血压患者肾功能下降的风险。并且随着患者的Hcy浓度升高这一风险也更加的明显 [26] 。

3) Hcy与心肌损害

目前研究结果下Hcy水平与高血压性心脏病、左心室肥厚的相关性存在争议。上海一大型社区研究发现,社区居住的老年人群中,无论如何调整混杂因素,Hcy水平和HHcy与心脏损害(由左心室质量指数LVMI和左心室舒张功能障碍LVDD表示)之间没有关联 [24] 。但是有的研究得出的结论不尽相同,Yu S等人对中国农村地区的研究发现,在患有代谢综合征(MetS)的人群中:HHcy对左心室肥厚有独立影响。MetS和HHcy的综合作用可能会增加这一影响 [27] 。HHcy已被证实在患有高血压,糖尿病的人群中,其与左室壁结构改变有关 [28] [29] [30] 。而一个比较新的研究得出的结论是糖尿病和高血压可导致左心室肥厚,而不依赖于Hcy水平 [31] 。依据当前的研究结论,倾向于心脏相关损害主要由患者的原发疾病造成,但Hcy是否会引起和加重心脏损害还需要进一步的研究。

5. 相关机制

目前相关机制尚不明确。Hcy通过氧化应激产生血管内皮损伤因子,刺激血管壁,使血管舒张因子(主要是一氧化氮)减少,从而导致高血压 [32] 。Hcy还能直接导致血管平滑肌细胞增生 [33] ,加速动脉硬化,促进血管壁脂质沉积 [34] ,增加血管平滑肌细胞中钙离子浓度 [35] ,降低血管顺应性。近年来氧化应激和内质网应激是研究的热门方向,目前与其相关的机制观点是:HHcy促进氧自由基的形成,降低氧化还原电位,对血管壁中血管扩张因子的生物合成和功能产生不利影响,有助于抑制内皮细胞分裂与强烈的肌细胞增殖和迁移,并损害血管壁中细胞外基质成分的产生。此外,高水平的Hcy及其衍生物有助于LDL和HDL颗粒的修饰,凝血和纤维蛋白溶解中的炎症和紊乱。HHcy对内皮的影响的生化作用可导致内皮细胞损伤,血管舒张功能障碍,并通过其对血管壁重塑的影响降低其灵活性。这些变化导致血压升高,加强高血压的发展和这种疾病的患者的靶器官损伤 [36] 。

6. 治疗方法

针对不同病因导致的HHcy有不同的治疗方法。但主要的原则是补充缺乏的相应维生素:均衡饮食,补充叶酸、钴胺素、维生素B6或甜菜碱,改善营养代谢状况 [37] 。刘等人通过研究马来酸依那普利叶酸片对H型高血压患者的降压作用及对血清Hcy水平的影响。得出结论:马来酸依那普利叶酸片既能有效降低H型高血压患者血压,又可以降低血清Hcy水平,改善靶器官功能,减少心血管事件的发生,值得推广应用 [38] 。有试验表明抗同型半胱氨酸治疗(例如补充叶酸)可有效降低血压和心血管疾病的风险。对12项随机对照临床试验的荟萃分析发现,每天补充5000~10,000 μg叶酸至少6周可将肱动脉收缩压降低2.03 mmHg [39] 。Li及其同事对30项随机对照试验荟萃分析显示,补充叶酸可分别降低中风和整体心血管疾病的风险10%和4% [40] 。近几年中医方面的相关治疗也逐渐受到重视,中医治疗从整体观念出发,辅助西医治疗,改善患者的临床不适症状有较好的疗效,但远期效益存在争议 [41] 。

7. 小结

Hcy与高血压靶器官损害的关系密切,目前尚不能明确相关机制,总的来说,Hcy在高血压疾病进展中有促进作用,并且有加重高血压靶器官损害这一效应,降低Hcy水平可延缓其进展,至于Hcy是否会导致高血压和其与高血压相关的左心室肥厚是否有关还需进一步研究。

NOTES

*通讯作者。

参考文献

[1] Yasin, Y.J., Banoub, J.A.M. and Kanchan, T. (2019) GBD 2017 Risk Factor Collaborators. Global, Regional, and Na-tional Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clus-ters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (vol 392, pg 1923, 2017). The Lancet, 393, E44.
[2] 中国高血压防治指南修订委员会, 等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56.
[3] Wang, Z.W., Chen, Z., Zhang, L.F., et al. (2018) Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation, 137, 2344-2356.
https://doi.org/10.1161/CIRCULATIONAHA.117.032380
[4] Lembo, M., Pacella, D., Manzi, M.V., et al. (2023) Hypertension-Mediated Organ Damage Involving Multiple Sites Is an Independent Risk Factor for Cardio-vascular Events. European Heart Journal Open, 3, oead102.
https://doi.org/10.1093/ehjopen/oead102
[5] 李建平, 卢新政, 霍勇, 等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志, 2016, 24(2): 123-127.
[6] Li, J., Jiang, S., Zhang, Y., et al. (2015) H-Type Hypertension and Risk of Stroke in Chinese Adults: A Prospective, Nested Case-Control Study. Journal of Translational Internal Medicine, 3, 171-178.
https://doi.org/10.1515/jtim-2015-0027
[7] McCully, K.S. (1996) Homocysteine and Vascular Disease. Nature Medicine, 2, 386-389.
https://doi.org/10.1038/nm0496-386
[8] Baric, I., Staufner, C., Augoustides-Savvopoulou, P., et al. (2017) Con-sensus Recommendations for the Diagnosis, Treatment and Follow-Up of Inherited Methylation Disorders. Journal of Inherited Metabolic Disease, 40, 5-20.
https://doi.org/10.1007/s10545-016-9972-7
[9] Zaric, B.L., Obradovic, M., Bajic, V., et al. (2019) Homocysteine and Hyperhomocysteinaemia. Current Medicinal Chemistry, 26, 2948-2961.
https://doi.org/10.2174/0929867325666180313105949
[10] Kucha, W., Seifu, D., Tirsit, A., et al. (2022) Folate, Vitamin B12, and Homocysteine Levels in Women with Neural Tube Defect-Affected Pregnancy in Addis Ababa, Ethio-pia. Frontiers in Nutrition, 9, Article ID: 873900.
https://doi.org/10.3389/fnut.2022.873900
[11] 梁喆, 范芳芳, 张岩, 等. 中国高血压人群中H型高血压的比率和特征及与美国人群的比较[J]. 北京大学学报(医学版), 2022, 54(5): 1028-1037.
[12] Unger, T., Borghi, C., Char-char, F., et al. (2020) 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Journal of Hypertension, 38, 982-1004.
https://doi.org/10.1097/HJH.0000000000002453
[13] McCully, K.S. (1969) Vascu-lar Pathology of Homocysteinemia: Implications for the Pathogenesis of Arteriosclerosis. The American Journal of Pa-thology, 56, 111-128.
[14] Liu, X., Sun, N., Yu, T., et al. (2016) Independent and Joint Association of Blood Pressure, Serum Total Homocysteine, and Fasting Serum Glucose Levels with Brachial-Ankle Pulse Wave Velocity in Chinese Hypertensive Adults. International Heart Journal, 57, 627-633.
https://doi.org/10.1536/ihj.16-082
[15] Huo, Y., Li, J., Qin, X., et al. (2015) Efficacy of Folic Acid Therapy in Primary Prevention of Stroke among Adults with Hyper-tension in China: The CSPPT Randomized Clinical Trial. Journal of the American Medical Association, 313, 1325-1335.
https://doi.org/10.1001/jama.2015.2274
[16] 李涛, 张晶晶. H型高血压中西医研究简况[J]. 实用中医内科杂志, 2017, 31(5): 82-84.
[17] Li, Z., Guo, X., Chen, S., et al. (2016) Hyperhomocysteinemia Independently Associated with the Risk of Hypertension: A Cross-Sectional Study from Rural China. Journal of Human Hypertension, 30, 508-512.
https://doi.org/10.1038/jhh.2015.75
[18] Tao, L.-X., Yang, K., Wu, J., et al. (2018) Association between Plasma Homocysteine and Hypertension: Results from a Cross-Sectional and Longitudinal Analysis in Beijing’s Adult Popula-tion from 2012 to 2017. Journal of Clinical Hypertension, 20, 1624-1632.
https://doi.org/10.1111/jch.13398
[19] Wu, H., Wang, B., Ban, Q., et al. (2018) Association of Total Homocysteine with Blood Pressure in a General Population of Chinese Adults: A Cross-Sectional Study in Jiangsu Province, China. BMJ Open, 8, e021103.
https://doi.org/10.1136/bmjopen-2017-021103
[20] Lu, H., Lu, Z.H., Li, P.G., et al. (2010) Elevated Homocysteine and Hypertension in Xinjiiang Province, China. Ethnicity & Disease, 20, 7-10.
[21] Yang, B., Fan, S., Zhi, X., et al. (2017) Interactions of Homocysteine and Conventional Predisposing Factors on Hypertension in Chinese Adults. Jour-nal of Clinical Hypertension, 19, 1162-1170.
https://doi.org/10.1111/jch.13075
[22] Wang, H., Liu, J., Wang, Q., et al. (2013) Descriptive Study of Possible Link between Cardio-Ankle Vascular Index and Homocysteine in Vascu-lar-Related Diseases. BMJ Open, 3, e002483.
https://doi.org/10.1136/bmjopen-2012-002483
[23] Elias, M.F., Crichton, G.E. and Abhayaratna, W.P. (2015) In-teractions between Plasma Homocysteine and Arterial Stiffness in Chronic Kidney Disease in Community-Dwelling In-dividuals: The Maine-Syracuse Study. Journal of Human Hypertension, 29, 726-731.
https://doi.org/10.1038/jhh.2015.17
[24] Ren, Z., Zhang, J., Yu, S., et al. (2021) Hypertension-Mediated Organ Damage Correlates with Serum Homocysteine Level in Community-Dwelling Elderly Chinese: The North Shanghai Study. Frontiers in Cardiovascular Medicine, 8, Article ID: 662741.
https://doi.org/10.3389/fcvm.2021.662741
[25] Levi, A., Cohen, E., Levi, M., et al. (2014) Elevated Serum Ho-mocysteine Is a Predictor of Accelerated Decline in Renal Function and Chronic Kidney Disease: A Historical Prospec-tive Study. European Journal of Internal Medicine, 25, 951-955.
https://doi.org/10.1016/j.ejim.2014.10.014
[26] Liu, C.L., Lin, L. and Xu, R. (2020) Elevated Homocysteine and Differential Risks of the Renal Function Decline in Hypertensive Patients. Clinical and Experimental Hypertension, 42, 565-570.
https://doi.org/10.1080/10641963.2020.1739698
[27] Yu, S., Chen, Y., Yang, H., et al. (2020) Hyperhomocyste-inemia Accompany with Metabolic Syndrome Increase the Risk of Left Ventricular Hypertrophy in Rural Chinese. BMC Cardiovascular Disorders, 20, Article No. 44.
https://doi.org/10.1186/s12872-020-01350-2
[28] Kundi, H., Kiziltunc, E., Ates, I., et al. (2017) Association be-tween Plasma Homocysteine Levels and End-Organ Damage in Newly Diagnosed Type 2 Diabetes Mellitus Patients. Endocrine Research, 42, 36-41.
https://doi.org/10.3109/07435800.2016.1171235
[29] Lin, B.-Y., Li, P., Wu, X.-D., et al. (2020) The Relationship between Homocysteine, Blood Pressure Variability, and Left Ventricular Hypertrophy in Patients with Essential Hyper-tension: An Observational Study. Advances in Therapy, 37, 381-389.
https://doi.org/10.1007/s12325-019-01154-7
[30] Gormus, U., Ozmen, D., Ozmen, B., et al. (2010) Serum N-terminal-pro-brain Natriuretic Peptide (NT-pro-BNP) and Homocysteine Levels in Type 2 Diabetic Patients with Asymptomatic Left Ventricular Diastolic Dysfunction. Diabetes Research and Clinical Practice, 87, 51-56.
https://doi.org/10.1016/j.diabres.2009.10.010
[31] Li, T., Chen, S., Guo, X., et al. (2017) Impact of Hypertension with or without Diabetes on Left Ventricular Remodeling in Rural Chinese Population: A Cross-Sectional Study. BMC Cardiovascular Disorders, 17, Article No. 206.
https://doi.org/10.1186/s12872-017-0642-y
[32] Pinna, A., Zinellu, A., Tendas, D., et al. (2016) Plasma Homo-cysteine and Asymmetrical Dimethyl-L-Arginine (ADMA) and Whole Blood DNA Methylation in Early and Neovascu-lar Age-Related Macular Degeneration: A Pilot Study. Current Eye Research, 41, 88-96.
https://doi.org/10.3109/02713683.2014.1002044
[33] 张宇, 王林. 同型半胱氨酸与H型高血压研究进展[J]. 中华老年病研究电子杂志, 2016, 3(1): 30-38.
[34] 张丽英, 刘彦春, 高铭枢. H型高血压合并冠心病与高同型半胱氨酸血症的关系探讨[J]. 中西医结合心脑血管病杂志, 2017, 15(7): 830-832.
[35] Sen, U., Moshal, K.S., Tyagi, N., et al. (2006) Homocysteine-Induced Myofibroblast Differentiation in Mouse Aortic Endothelial Cells. Journal of Cellular Physiology, 209, 767-774.
https://doi.org/10.1002/jcp.20752
[36] Han, L., Liu, Y., Wang, C., et al. (2017) Determinants of Hyperhomocysteinemia in Healthy and Hypertensive Subjects: A Population-Based Study and System-atic Review. Clinical Nutrition, 36, 1215-1230.
https://doi.org/10.1016/j.clnu.2016.11.011
[37] 李东晓, 张尧, 张宏武, 等. 高同型半胱氨酸血症的诊断、治疗与预防专家共识[J]. 罕少疾病杂志, 2022, 29(6): 1-4.
[38] 刘神幼, 周天玖, 曾莹. 依那普利叶酸片治疗H型高血压患者的疗效及对血清同型半胱氨酸的影响[J]. 北京医学, 2021, 43(5): 466-468.
[39] McRae, M.P. (2009) High-Dose Folic Acid Supplementation Effects on Endothelial Function and Blood Pressure in Hypertensive Patients: A Meta-Analysis of Randomized Controlled Clinical Trials. Journal of Chiropractic Medicine, 8, 15-24.
https://doi.org/10.1016/j.jcm.2008.09.001
[40] Li, Y.P., Huang, T.Y., Zheng, Y., et al. (2016) Folic Acid Supple-mentation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 5, e003768.
https://doi.org/10.1161/JAHA.116.003768
[41] 黄荣铝, 李景君, 李永春, 等. 中药治疗H型高血压的研究进展[J]. 中国处方药, 2022, 20(7): 160-162.